The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SBS | -41.85% | -84.59% | -31.18% | +440% |
| S&P | +13.95% | +78.35% | +12.25% | +601% |
STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. It operates through the following segments: Instrumentation, Diatron, Smart Consumables, and Other Activities. The Instrumentation segment consults, designs, develops and produces fully automated solutions for its partners in the fields of diagnostics including blood banking. The Diatron segment comprises the business with systems, system components, consumables and tests in the low throughput hematology and clinical chemistry segment. The Smart Consumables segment includes the business with developing and manufacturing smart consumables in the fields of diagnostics, life sciences, and medical technology. The Other Activities segment covers the development of work flow software for networking several analyzer systems and the development and sale of scientific materials and technologies. The company was founded by Hermann Leistner in 1979 and is headquartered in Birkenfeld, Germany.
No news articles found for Stratec Se.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $57.00M | -0.4% |
| Gross Profit | $13.30M | -19.5% |
| Gross Margin | 23.34% | -5.5% |
| Market Cap | $348.27M | -35.0% |
| Market Cap / Employee | $245.26K | -33.0% |
| Employees | 1.4K | -2.9% |
| Net Income | $1.50M | 173.4% |
| EBITDA | $7.57M | -9.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $22.40M | -32.4% |
| Accounts Receivable | $49.49M | 19.6% |
| Inventory | 126.4 | -15.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $116.95M | 24.9% |
| Short Term Debt | $15.29M | -74.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Return On Assets | 3.41% | 0.0% |
| Return On Invested Capital | 8.68% | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | $19.40M | 0.0% |
| Operating Free Cash Flow | $23.28M | 0.0% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 40.24 | 38.03 | 53.48 | 22.61 | - |
| Price to Book | 2.42 | 2.35 | 1.59 | 1.47 | -29.75% |
| Price to Sales | 1.94 | 2.17 | 2.14 | 1.41 | - |
| Price to Tangible Book Value | 4.80 | 4.74 | 3.17 | 2.81 | -30.97% |
| Price to Free Cash Flow TTM | 31.01 | 26.22 | 11.27 | - | |
| Enterprise Value to EBITDA | 64.75 | 78.69 | 20.64 | 60.52 | -42.84% |
| Free Cash Flow Yield | 3.2% | 3.8% | 8.9% | - | |
| Return on Equity | 5.3% | 6.5% | 4.4% | 6.7% | - |
| Total Debt | $150.07M | $152.54M | $130.53M | $132.24M | -6.92% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
